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INTRODUCTION 
Benign Prostatic Hyperplasia 
Historically, Benign prostatic hyperplasia(BPH) has been a major 
focus of urologic practice and surgery. Benign Prostatic Hyperplasia is 
correctly defined as histological enlargement of the prostate gland from 
progressive hyperplasia of stromal and glandular prostatic cells. Clinical 
BPH refers to the lower urinary tract symptoms(LUTS) associated with 
benign prostatic enlargement causing varying degrees of bladder outlet 
obstruction. 
However a simplistic causal relationship among prostatic 
enlargement, progressive obstruction, lower urinary tract 
symptoms(LUTS), retention and complications of retention has been 
challenged by recognition of the incomplete overlap of prostatic 
enlargement with symptoms and obstruction. This caused a shift in the 
application of various modalities of BPH management with current focus 
on medical management rather than surgical therapy.  
Benign prostatic hyperplasia is a pathological process which 
contributes to, but is not the sole cause of lower urinary tract 
symptoms(LUTS).It is now clear that a significant proportion of patients 
who present with LUTS suffer from age related detrusor dysfunction 
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independent of benign prostatic enlargement(1).While evaluating men 
with LUTS, we can stratify them into mild, moderate and severe 
symptomatic groups according to a standardized symptom questionnaire 
like the IPSS (International Prostate Symptom Score)(2). 
Bladder Outlet Obstruction(BOO) may itself induce a variety of 
neural alterations in the bladder which may contribute to symptoms. Men 
with benign prostatic enlargement presumably have an increase in the 
total prostate volume because of BPH. BPH may or may not produce 
clinically significant LUTS and may or may not produce urodynamically 
proven bladder outlet obstruction. 
         Histologically BPH is characterized by an increased number of 
epithelial and stromal cells in the periurethral area of the prostate. The 
precise molecular etiology of this hyperplastic process is uncertain. The 
observed increase in cell number may be due to epithelial and stromal 
proliferation or to impaired programmed cell death leading to cellular 
accumulation (3).Androgens, estrogens, stromal-epithelial interactions, 
growth factors and neurotransmitters may play a role either solely or in 
combination in the etiology of this hyperplastic process(3). 
McNeal demonstrated that BPH first develops in the periurethral 
transition zone of the prostate. However, the transition zone also enlarges 
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with age unrelated to development of nodules. The size of the prostate 
does not correlate with degree of obstruction. Thus, other factors like 
dynamic urethral resistance prostate capsule and anatomic pleomorphism 
are more important in production of clinical symptoms than the absolute 
size of the gland (4). 
While evaluating LUTS with the standardized questionnaires, in 
addition to mere enumeration of symptoms by frequency of occurrence; 
the bother associated with symptoms, interference with activities of daily 
living and the impact on quality of life are important distinguishing 
characteristics(2). 
Recent studies have shown that there exists only a weak 
relationship between prostate size, severity of BOO and severity of 
symptoms (5,6). The complex of symptoms referred to as LUTS is not 
specific for BPH. Aging men with a variety of lower urinary tract 
pathological processes may produce similar symptoms. The diagnostic 
challenge is to establish that the symptoms are in fact, a result of BPH. 
This is the primary focus of initial evaluation and diagnostic testing of 
prostate. 
Digital Rectal Examination(DRE) establishes the approximate size 
of the prostate gland, although its reliability across observers is 
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considered poor (7). In addition, DRE underestimates the size of the 
prostate by 25 to 50% when compared with ultrasonogram(7). 
Ultrasound, either transabdominal or transrectal are more accurate in 
assessing prostate size(8). 
Transrectal ultrasound (TRUS) volume measurements using 
prostate ellipsoid volume formula are the most widely accepted measure 
of prostate volume with reasonable statistical performance when 
measured by several well trained examiners(9).TRUS measured prostate 
volume has been found to increase slowly and steadily with advancing 
age(10). MRI prostatic volume is 10% larger when compared to TRUS. 
The total prostate volume increases from 25ml in 40 yr old patients to 
45ml in 70 yr old patients. The transitional zone volume increased from 
15 to 25 ml for similarly aged men (11). 
Infravesical obstruction can be measured only by invasive pressure 
flow studies. Uroflowmetry or free flow rates promise at best an indirect 
measure for the probability of obstruction being present. It is commonly 
accepted that a maximum flow rate of greater than 15ml/sec indicates low 
probability of obstruction when compared with a flow rate of less than 10 
ml/sec which indicates high probability (12). However, its utility is low 
as flow rate is dependent on voided volume. There is no single 
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universally accepted nomogram. A high degree of day to day variability 
and diurnal variation further reduces its usefulness in defining disease. 
 Pressure flow studies are most useful for distinguishing between 
urethral obstruction and impaired detrusor contractibility(13).The 
inclusion of pressure flow studies in preoperative evaluation and 
indications for surgery reduced the failure rate from 28 to 12%(14). Due 
to absence of strong correlation between symptom scores, maximal flow 
rate and prostate volume, recent attention has been focused on co-
relations between the transition zone of the prostate and physiologic 
measures of obstruction. Kaplan and co-authors first reported a strong co-
relation between transition zone volume and symptoms along with peak 
urine flow and unexpectedly also with detrusor pressure at peak flow(15). 
Invasive pressure flow studies are not performed in community based 
studies and thus comparative data from population based studies are not 
available. 
Data from Olmstead county study suggest no stronger co-relation 
between symptoms and peak flow rate with transition zone volume than 
with total prostate volume (11). The TZ index weakly correlated with 
AUA symptom index and peak flows in a large BPH treatment trial(16). 
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          Therefore the correlation between non invasive markers of BOO in 
BPH are modest in community based population studies and weak in 
BPH trial populations. We thus decided to restudy the role of transition 
zone index in the Indian population in comparision with other 
noninvasive markers of obstruction like uroflowmetry, postvoid residual 
urine, prostate volume and detrusor wall thickness. The performance 
characteristics of transition zone index when compared to the gold 
standard pressure flow studies was also analysed. 
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AIMS AND OBJECTIVES 
 The primary objective of our study was to evaluate the role 
of transition zone index in assessing bladder outflow 
obstruction due to benign prostatic hyperplasia. 
 The secondary objective was to determine correlation of 
transition zone index with IPSS score, Abrams-Griffith  
number and urinary flow rates 
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REVIEW OF LITERATURE 
Benign Prostatic Hyperplasia (BPH) is correctly defined 
histologically as enlargement of the prostate gland from progressive 
hyperplasia of stromal and glandular prostatic cells. Clinical BPH refers 
to the lower urinary tract symptoms(LUTS) associated with benign 
prostatic enlargement causing varying degrees of bladder outlet 
obstruction. 
Etiology 
BPH is characterized histologically as a progressive enlargement of 
the prostate gland resulting from a nonmalignant proliferative process 
that includes both epithelial and stromal elements. Growth results from 
proliferation of fibroblasts or myofibroblasts and epithelial glandular 
elements near the urethra in the transition zone of the prostate gland. The 
hyperplastic process is multifocal and exhibits a variegated histology with 
variable proportions of stromal nodules and glandular hyperplasia(17). 
Endocrine factors 
Androgens are not only required for normal proliferation and 
differentiation but also to actively inhibit cell death. In experimental BPH 
produced by androgens, despite a significant increase in gland size, there 
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is actually a reduction in the rate of DNA synthesis (18). It is known that 
the prostatic levels of dihydrotestosteroneand androgen receptors remain 
high with aging despite the fact that peripheral levels of testosterone are 
decreasing. Ninety percent of prostatic androgen is in the form of 
dihydrotestosterone which is more potent and binds with greater affinity 
to the androgen receptor. The hormone receptor binds to specific DNA 
sites in the nucleus which results in increased transcription of androgen 
dependent genes and ultimately stimulation of protein synthesis (19). 
Androgen withdrawal may exert its effect on prostate through vascular 
effects, inactivation of key androgen dependent genes like PSA and 
activation of key genes involved in programmed cell death (20). 
Apoptosis 
Programmed cell death is a physiologic mechanism crucialto the 
maintainence of normal glandular homeostasis. Apoptosis occurs without 
activation if the immune system but requires RNA and protein synthesis. 
Following castration,active cell death is increased in luminal epithelium 
as well as in distal region of ducts which is modulated by the TNF-β 
family of cytokines (21). 
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Embryonic Reawakening Theory 
The prostatic stromal and epithelial cells maintain a paracrine type 
of communication. BPH may be due to a defect in the stromal component 
that normally inhibits cellular proliferation, resulting in a loss of the 
normal braking mechanism. The process of new gland formation in the 
hyperplastic prostate suggests a “reawakening” of embryonic processes in 
which underlying prostatic stroma induces epithelial cell  
development (22). 
Growth Factors 
Growth factors are small peptide molecules that stimulate, or in 
some cases inhibit, cell division and differentiation processes. Cells that 
respond to growth factors have on their surface receptors specific for that 
growth factor that in turn are linked to a variety of transmembrane and 
intracellular signaling mechanisms. Interactions between growth factors 
and steroid hormones may alter the balance of cell proliferation versus 
cell death to produce BPH. Lawson's group was the first to demonstrate 
that extracts of BPH stimulate cellular growth. This putative prostatic 
growth factor was subsequently found on sequence analysis to be basic 
fibroblastic growth factor (b-FGF) (23). 
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Other Signaling Pathways 
Sympathetic signaling pathways are important in the 
pathophysiology of LUTS. There is increasing evidence that sympathetic 
pathways may be important in the pathogenesis of the hyperplastic 
growth process. Alpha blockade, in some model systems, can induce 
apoptosis. Alpha-Adrenergic pathways can also modulate the smooth 
muscle cell phenotype in the prostate. All the components of the renin-
angiotensin system (RAS) are present in prostatic tissue and may be 
activated in BPH (24,25). 
Anatomy of BPH 
The proposed organization of the fetal, newborn, and adult prostate 
into discrete lobes has been regarded with skepticism .With a focus on the 
development of benign prostatic hyperplasia (BPH), Franks 
conceptualized a prostate with an inner (urethral) and outer glandular 
configuration (26). McNeal and Lowsley suggested that the urethral 
(inner) glands should be considered separately from the prostate and its 
intrinsic architecture (22,27). However, the major physiologic and 
biochemical similarities of these glands and those of the prostatic 
parenchyma weigh against this concept. Tissell and Salander, who used 
meticulous dissection techniques, observed subdivisions of the prostate 
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gland that had several similarities to those reported by McNeal, but they 
interpreted these as evidence for the existence of prostatic 
lobes(28).McNeal observed that the urethra separates the prostate into 
ventral (fibromuscular) and dorsal (glandular) portions. McNeal separated 
the glandular prostate into four distinct regions: peripheral zone, central 
zone, transition zone, and periurethral gland region. The peripheral zone 
constitutes approx 75% of the glandular prostate.Its ductal system enters 
the urethra along the posterolateral recesses of the urethra and extends 
from the verumontanum distally to the prostatic apex. The wedge-shaped 
central zone, the base of which is positioned superiorly at the bladder 
neck, occupies approx 20% of the glandular prostate. Its ductal network 
closely follows the ejaculatory ducts to the urethra and empties adjacent 
to orifices of the ejaculatory ducts on the apex of the verumontanum(22). 
The transition zone, accounting for 4–5% of the adult glandular prostate, 
is not well defined in the prepubertal prostate. It consists of two modest 
lobules of paraurethral tissue anterior to the peripheral zone. Its ducts 
empty in the posterior lateral recess of the urethra just proximal to 
peripheral zone ducts. The transition zone is lateral to McNeal’s 
preprostatic sphincter, a smooth muscle cylinder enveloping the proximal 
urethra from the bladder neck to the base of the verumontanum. The last 
anatomically discrete area within the glandular prostate is the periurethral 
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gland region, which represents less than 1% of the total volume of the 
glandular prostate. Its ductal network represents a more proximal 
extension of the networks of the peripheral and transition zone areas. 
These regions have differing acinar, stromal, and cellular configurations. 
McNeal postulated that the anatomic and histologic similarities of the 
peripheral andtransition zones and periurethral gland region were 
attributable to a common urogenital sinus embryonic origin (22).The 
anterior fibromuscular stroma forms an apron that extends distally, covers 
the entire anterolateral aspect of the glandular prostate, and is responsible 
for the anterior convexity of the prostate gland. It represents 
approximately one-third of the tissue within the prostate capsule (29). 
This unusually distinct area, composed predominantly of smooth muscle 
fibers, maintains continuity proximally with the detrusor muscle fibers of 
the bladder neck. Contraction of the circular smooth muscle of the 
bladder neck and preprostatic sphincter assists in the elimination of 
secretions within the prostatic urethra; this smooth muscle probably 
forms the major working element of the internal urethral sphincter. The 
anterior and anterolateral aspects of the prostate contain smooth and 
skeletal muscle, joining the fibers of the external sphincter and 
augmenting urinary control (30). 
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  McNeal demonstrated that BPH first develops in the periurethral 
transition zone of the prostate. Although early TZ nodules appear to occur 
either within or just adjacent to preprostatic sphincter, as the disease 
progresses and the number of small nodules increase, they can be found 
in any portion of the transition zone or periurethral zone. However, the 
transition zone also enlarges with age unrelated to development of 
nodules. The size of the prostate does not correlate with degree of 
obstruction. Thus, other factors like dynamic urethral resistance prostate 
capsule and anatomic pleomorphism are more important in production of 
clinical symptoms than the absolute size of the gland (4,22). 
Natural history of BPH 
The first pathologic evidence of BPH occurs in less than 10% of 
men in the 31- to 40-yr-old group(26,31). Thus, either the initiating factor 
is present in most men of this age and only clinically evident in a few, or 
young men with recognizable BPH have a discrepancy between 
physiologic and chronologic aging. Evidence of histologic and anatomic 
BPH increases with age; by the ninth decade approx 90% of men have 
histologic evidence of BPH, and more than half have anatomic evidence 
of BPH (31). The initial lesion of BPH typically occurs in the periurethral 
area proximal to the verumontanum. Although descriptions of the ductal 
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and glandular structure of this area vary, it is generally agreed that BPH 
arises from an inner set of prostatic ducts and glands that reside within 
the urethral wall or adjacent to it. The paraurethral portion of this tissue 
comprises approx 5% of the normal gland and is designated the transition 
zone. However, once the process is initiated, all elements of the normal 
prostate, both stromal and glandular, participate to a variable degree in its 
progression. Glands in the hyperplastic nodules have the capacity to bud 
and form new ducts and acini; in contrast to normal tissue, these new 
glandular elements grow toward each other. Both the average weight of 
the prostate and the incidence of prostatectomy by decade suggest that 
once BPH develops, it is progressive in most men (32). 
Effect of BPH on the bladder 
The development and progression of mechanical obstruction from 
the prostatic mass has been the traditional focus regarding the sequelae 
resulting from BPH. The perception that the mass and configuration of 
the hyperplasia dictated the degree of outflow blockage 
undoubtedlyresulted from early experience treating patients with acute 
and chronic urinary retention. Renal failure, urinary tract infection, and 
calculi were common indications for various approaches to relieve 
bladder neck obstruction. The reversal of these serious secondary 
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phenomena and restoration of improved voiding patterns reinforced the 
mass concept. Failures in both of these therapeutic goals were 
overshadowed by the frequent correction of the problems that existed. In 
the last 20 years, intrinsic prostatic tension from contracting prostate 
stromal smooth muscle and/or extrinsic tension on the BPH prostate mass 
by a contracting prostate capsule have been proposed as having 
potentially important roles in primary or persistent bladder outlet 
obstruction(33, 34, 35).The proposed role of stromal smooth muscle-
mediated increased intrinsic prostate tension has been reinforced 
substantially by in vitro physiologic and, to a lesser degree, by clinical 
observations with both α-adrenergic agonists and antagonists(34). The 
proposed role of peripheral capsular tension on bladder outlet obstruction 
is supported by the results of transurethral incision(36). Although α -
agonist mechanisms may adversely impact voiding in a variety of ways 
that may complement the effects of BPH treatment, these secondary 
phenomena are unlikely to play a direct role in the primary BPH-
mediated effects on voiding.  
BPH-mediated bladder outlet obstruction results in a series of 
changes in bladder tissue mass, composition, and function. It also affects 
blood supply and nerve status and function. The degree and persistence of 
the obstruction is thought to play a pivotal role in the subsequent 
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anatomic and functional bladder effects. Obstruction can be the primary 
source of physiologic change, with results varying from hyper function 
and hyperirritability to nonfunction or atony. Evaluation of this spectrum 
of functional states can be difficult and confusing. Consequently, 
evidence of bladder changes associated with outflow obstruction is 
derived largely from observations in animals. In general, partial bladder 
obstruction initially results in reversible detrusor hypertrophy and 
increased bladder weight (37). The increased muscle mass is associated 
with increased intravesical pressure (38). The human models develop a 
thickened, trabeculated bladder in response to outflow obstruction. 
Moreover, obstruction is associated with increased collagen deposition 
and decreased compliance(37). Rabbits with bladder outlet obstruction 
show changes in detrusor muscle myosin phenotype, suggesting a trend to 
a dedifferentiated phenotype(37).The anatomic and physiologic 
alterations that occur in response to obstruction probably play a major 
role in the specific bladder and renal changes that occur in individual 
patients. Currently, loss of bladder compliance is most likely the principal 
factor in producing upper urinary tract functional and anatomic damage. 
Cellules, saccules, and diverticula are recognized related anatomic 
bladder changes that develop and progress unpredictably and may have 
clinical significance. Based on their extensive experience with the 
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pathophysiology of obstruction-induced bladder changes, Levin et al. 
suggested that bladder outlet obstruction should be relieved as soon as 
possible after diagnosis to maximize the opportunity for bladder  
recovery (37). 
 
Other Causes of LUTS 
Other causes of these symptoms gleaned from the history include 
urinary tract infection, prostatic obstruction, BPH, bladder cancer, 
prostate cancer, urolithiasis, urethral stricture disease, and neurological 
causes (e.g, Parkinson disease, cerebrovascular accident). In patients 
Pathophysiology of BPH 
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experiencing urinary frequency or polyuria, the symptoms may be caused 
by nonurological conditions, such as polydipsia, diabetes mellitus and 
diabetes insipidus. Similarly, nocturia may be associated with factors 
other than prostatic obstruction or BPH, including detrusor overactivity, 
sensory urgency, abnormal drinking patterns, congestive cardiac failure, 
venous insufficiency, or polydipsia. The use of prescription drugs and 
over the counter medications should be discussed because some 
medications affect detrusor contractility (eg, anticholinergics) or increase 
bladder outflow resistance (eg, alpha agonists). Bladder diaries and 
symptom questionnairesare useful as adjuncts to information acquired in 
the history (34). 
NON INVASIVE ASSESSMENT OF BENIGN PROSTATIC 
HYPERPLASIA- 
Digital Rectal Examination (DRE) 
A DRE and a focused neurologic examination should usually be 
performed to detect prostate or rectal malignancy, to evaluate anal 
sphincter tone and to rule out any neurologic problems that may cause the 
presenting symptoms(36). In addition, examination of the external 
genitalia is indicated to exclude meatal stenosis or a palpable urethral 
mass, and an abdominal examination is necessary to exclude an 
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overdistended, palpable bladder. The presence of induration is as 
important a finding as the presence of a nodule and should be correlated 
with a serum PSA value so that the need for prostatic biopsy can be 
assessed. 
DRE establishes the approximate size of the prostate gland. In 
patients who choose or require either medical or invasive therapy, 
estimation of prostate size is important to select the most appropriate 
pharmacologic or technical approach. Prostate size does not correlate 
precisely with symptom severity, degree of urodynamic obstruction, or 
treatment outcomes (7). If a more accurate measurement of prostate 
volume is needed to determine whether to perform open prostatectomy 
rather than transurethral resection of the prostate (TURP), ultrasound 
(transabdominal or transrectal) is more accurate than cystourethroscopy. 
It is now established that a larger gland is associated with a greater risk of 
disease progression and AUR (39). 
Symptom Scores in LUTS 
        Questionnaires are especially useful in evaluating patients in that 
they offer the patient and the physician an opportunity to efficiently 
record the nature, frequency of occurrence, severity, and degree of bother 
of the patient’s LUTS. Merely reading the questionnaire makes the 
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patients think more intently about their symptoms, but not all patients are 
compliant. Some do not answer the questions at all; others answer them 
without even thinking; and some do not understand the questions and 
answer them incorrectly. It is important, therefore that the patients be 
specifically queried for the accuracy of their answers. 
      The International Prostate Symptom Score(IPSS) also known as 
the American Urological Association Symptom Index has been 
recommended for the assessment of severity of patients’ LUTS. The IPSS 
was developed by the Measurement Committee of the AUA (2). Each 
question on the IPSS can yield 0 to 5 points, producing a total symptom 
score that can range from 0 to 35. This seven-question set is internally 
consistent (Cronbach's alpha, 0.85) and reliable (test-retest correlation, 
0.93). The index correlates strongly with patients' global ratings of their 
urinary difficulties (r = 0.78) and is sensitive to treatment response. The 
AUA score can be divided into “mild,” “moderate,” and “severe” 
symptom categories (2).Symptom impact on a patient's lifestyle must be 
considered as well. An intervention may make more sense for a 
moderately symptomatic patient who finds his symptoms very 
bothersome than for a severely symptomatic patient who finds his 
symptoms tolerable. Although the IPSS correlates well with quality of 
28 
life measures (40), there is still a need for sensitive BPH-specific quality 
of life instruments. 
           The Overactive Bladder Symptom Score, the Urgency Perception 
score and the Urgency Perception scale are the 3 questionnaires that focus 
on urgency associated symptoms, and these are useful in determining 
patient response to treatment. In addition, the Patient Global Impression 
of Improvement questionnaire is a simplistic assessment of how the 
patient feels after treatment, and it does not evaluate LUTS specifically. 
The King’s Health Questionnaire which is not a symptom score, focuses 
on the bother owing to LUTS and incontinence and on overall quality of 
life, including personal, social, and emotional perspectives(41). 
        Some questionnaires double as outcome instruments in assessing 
response to treatment. For example, LUTS Outcome score is used in 
patients receiving treatment for LUTS, and it combines subjective and 
objective parameters(42). This score may easily be ciphered with the data 
derived from the IPSS, uroflow, postvoid residual volume, voiding diary, 
and a single question regarding whether treatment administered resulted 
in cure, improvement, or same or worse status. 
           The voiding diary is an essential part of the workup; the time and 
volume of each void and a description of associated LUTS should be 
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noted. The voiding diary differs from a simple frequency-volume chart in 
that it not only incorporates frequency, voided volume, urge episodes, 
pad usage, and fluid intake but also includes data related to patient 
activities and allows patients to have a more thorough self-evaluation of 
their LUTS. Above all, the voiding diary allows the physician to assess a 
patient’s voiding patterns (i.e., frequency, nocturia, incontinent episodes) 
during his ordinary life activities. The maximum voided volume gleaned 
from the diary is useful as a guide for determining the optimal infusion 
rate during cystometry and for estimating the minimum volume that 
should be infused. For routine clinical practice, a 24hr voiding diary will 
suffice(43). 
Serum Prostate-Specific Antigen 
Prostate cancer can lead to LUTS by producing bladder outflow 
obstruction similar to BPH. Moreover, prostate cancer commonly 
coexists with BPH. In most men with a 10-year or greater life expectancy, 
the knowledge of concomitant prostate cancer may well alter 
management of the BPH component. The detection of a large nodular 
prostate cancer on DRE would no doubt alter therapy; however, the 
“early detection” of small volume prostate cancer in an 80-year-old man 
is unlikely to increase life expectancy. A PSA test and DRE increase the 
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detection rate of prostate cancer over DRE alone. Therefore, 
measurement of the serum PSA value should be performed in patients in 
whom the identification of cancer would clearly alter BPH management 
(44). There is significant overlap between the serum PSA values of men 
with BPH and men with clinically localized prostate cancer. Twenty-eight 
percent of men with histologically proven BPH have a serum PSA greater 
than 4.0 ng/ml (36). Serum PSA trends over time (PSA velocity), 
measurement of free versus complexed PSA, and PSA density may help 
to improve the specificity of PSA in men with BPH. 
In the absence of prostate cancer the PSA value can provide a 
guide to prostate volume and also provide an indication of the likelihood 
of response to pharmacotherapy with a 5α-reductase inhibitor.  
Uroflowmetry 
Uroflowmetry involves the electronic recording of the urinary flow 
rate throughout the course of micturition. It is a common, noninvasive 
urodynamic test used in the diagnostic evaluation of patients presenting 
with symptoms of BOO. The results of uroflowmetry are nonspecific for 
causes of the symptoms. For example, an abnormally low flow rate may 
be caused by an obstruction (e.g., hyperplastic prostate, urethral stricture, 
meatal stenosis) or by detrusor hypocontractility. The Agency for health 
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care policy and research (AHCPR) Guideline Panel concluded regarding 
uroflowmetry that (36): 
The peak flow rate (PFR; Qmax) more specifically identifies 
patients with BPH than does the average flow rate (Qave). 
Flow rate recording is the single best noninvasive urodynamic test 
to detect lower urinary tract obstruction. Current evidence, however, is 
insufficient to recommend a given “cutoff” value to document the 
appropriateness of therapy. 
A Qmax of less than 15 mL/s does not differentiate between 
obstruction and bladder decompensation. 
The Fourth International Consultation on BPH concluded that flow 
rate measurement represents a reproducible way to quantify the strength 
of the urinary stream and, when used in combination with symptom 
scores for a small subset of patients (20%), has a high probability of 
correctly characterizing whether there is BOO (44). 
Scott and coworkers (1967) and Shoukry and associates (1975) 
found that Qmax correlated better than symptoms with the presence or 
absence of obstruction as determined by pressure-flow 
studies(45,46).Qmax appears to predict surgical outcome in some studies. 
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In one study reported by Jensen and coworkers (1984), 53 patients 
underwent prostatectomy based on clinical indication alone. All three 
groups according to level of Qmax experienced improvements in their 
symptom score after surgery, but the group with a Qmax less than 10 
mL/s before treatment had a better overall subjective outcome as assessed 
by global subjective judgment(47).Very low rates do not appear to 
portend poor treatment outcome. In one study of 84 patients undergoing 
surgery for symptomatic BPH, patients with a preoperative Qmax less 
than 7 mL/s improved symptomatically as much as patients with a Qmax 
greater than 7 mL/s(48). 
Postvoid Residual Urine 
Postvoid residual (PVR) urine is the volume of fluid remaining in 
the bladder immediately after the completion of micturition. Studies 
indicate that PVR urine normally ranges from 0.09 to 2.24 mL, with the 
mean being 0.53 mL (49). Seventy-eight percent of normal men have 
PVRs of less than 5 mL, and 100% have volumes of less than 12 mL 
(50). The AHCPR BPH Guideline Panel reached the following 
conclusions regarding PVR (36):  
Residual urine volume does not correlate well with other signs or 
symptoms of clinical BPH 
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Large residual urine volumes may predict a slightly higher failure 
rate with a strategy of watchful waiting. However, the threshold volume 
defining a poorer outcome is uncertain. 
Residual urine volume can be measured with sufficient accuracy 
noninvasively by transabdominal ultrasonography. The measurement 
variation caused by the method is less than the biologic range of PVR 
variation. 
The Fourth International Consultation on BPH, initially 
recommended PVR determination in the initial assessment and during 
monitoring of patients under watchful waiting or other conservative 
treatment regimens (44). 
PVR measurement can be performed by noninvasive (ultrasound) 
and by invasive (catheterization) methods. The most common method is 
by ultrasound. Invasive techniques are accurate if performed correctly but 
carry a small risk of discomfort, urethral injury, UTI, and transient 
bacteremia (which has not been quantified in the literature). The test-
retest reliability of PVR volume is poor, regardless of the techniques 
used. Although repeated measurements may minimize the error, this is 
either costly (noninvasive techniques) or uncomfortable (invasive 
techniques) for the patient. Birch and coworkers (1988) reported that of 
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30 men with PBH, 66% had wide variations in PVR when three 
measurements were done on the same day. In 34% of patients, there was 
no difference among the three measurements. In 58%, at least two 
volumes were significantly different. In 8% of patients, all three were 
different. In most patients, two measurements were statistically similar 
whereas the third one yielded quite different results. They also found no 
correlation between the amount of residual urine and any cystoscopic or 
urodynamic findings, symptoms or the presence or absence of a history of 
UTIs(51). 
Most clinical studies demonstrate minimal correlation between 
PVR and baseline measurements of symptoms, flow rate, or urodynamic 
measures of obstruction (52). 
However, Neal and associates (1987) found a significant 
association in 253 men between PVR, age, “below normal” Qmax, and 
high urethral resistance. Low voiding pressure, however, did not correlate 
well with PVR. The authors concluded that outflow obstruction is related 
to the development of increasing amounts of PVR urine(53). In the AUA 
Outcome Study, Barry and colleagues (1993) found a significant 
correlation between high PVR and low flow rates but no correlation with 
IPSS(54). 
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High PVR does predict a slightly higher failure rate for watchful 
waiting. In summary, PVR is best viewed as a “safety parameter.”Men 
with significant PVRs should be monitored more closely if they elect 
nonsurgical therapy. 
Ultrasound of the Prostate 
TRUS of the prostate, first described by Wantanabe and colleagues 
in1968, was expanded to routine clinical use with improvements in 
ultrasound technology and the introduction of the TRUS-guided 
systematic sextant biopsy protocol by Hodge and associates (55). TRUS 
technology has become a mainstay of many image-guided prostate 
interventions, including prostate biopsy, brachytherapy, cryotherapy, and 
high-intensity focused ultrasound (HIFU), as well as being used in the 
evaluation of appropriate patients for treatment of benign prostatic 
hyperplasia. 
Ultrasonographic Anatomy of the Prostate 
The prostate lies between the bladder neck and the urogenital 
diaphragm, just anterior to the rectum, an ideal position to be imaged via 
TRUS. The prostate gland is traditionally described based on a pathologic 
zonal architecture. These divisions consist of the anterior fibromuscular 
stroma (AFS) that is devoid of glandular tissue, transition zone (TZ), 
central zone (CZ), periurethral zone, and peripheral zone (PZ). 
Unfortunately, these regions are not visible sonographically as distinct 
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entities. Figure showing the normal TRUS anatomy of the prostate and 
also the zonal anatomy at the level of verumontanum. 
 
 
However, the TZ may often be discernible from the PZ and CZ, 
particularly in glands with significant BPH. Located posteriorly, the 
normal CZ and PZ, from which a majority of adenocarcinomas arise, 
have a homogeneous echogenic appearance whereas the anteriorly 
situated TZ is more heterogeneous. Frequently, calcifications along the 
surgical capsule known as “corpora amylacea” highlight the plane 
TRUS anatomy of prostate: AFS- anterior fibromuscular stroma , CZ-central zone, PZ-
peripheral zone, TZ-transition zone, U-urethra, B-bladder, EJD-ejaculatory duct 
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between the PZ and TZ (56).The prostatic urethra traverses the length of 
the gland in the midline and thus must be imaged in the sagittal plane to 
be simultaneously viewed along the entirety of its course. The distended 
urethral lumen has a hypoechoic appearance whereas periurethral 
calcifications may produce a thin echogenic outline. The smooth muscle 
of the internal sphincter extends from the bladder neck, encircling the 
urethra to the level of the verumontanum. These muscle fibers may be 
visualized sonographically as a hypoechoic ring around the upper 
prostatic urethra, giving it a funneled appearance proximally as it arises 
from the bladder neck. On reaching the verumontanum the urethra angles 
anteriorly and runs through the remainder of the gland to exit at the apex 
of the prostate. This angle gives the prostatic urethra an anteriorly 
concave appearance when viewed along its entire course in the sagittal 
plane.  
Figure showing Gray scale TRUS image of prostate showing the 
centrally running urethra.  
 
Midline hypoechoic urethra represented as a star 
38 
Prostate Volume Calculation 
Prostate volume can be calculated through a variety of formulas. 
Volume calculation requires measurement of up to three prostate 
dimensions. In the axial plane, the transverse and anteroposterior (AP) 
dimensions are measured at the point of widest transverse diameter. The 
longitudinal dimension is measured in the sagittal plane just off the 
midline because the bladder neck may obscure the cephalad extent of the 
gland. Most formulas assume that the gland conforms to an ideal 
geometric shape: either an ellipse (π/6 × transverse diameter × AP 
diameter × longitudinal diameter), sphere (π/6 × transverse diameter3), or 
a prolate (egg shaped) spheroid (π/6 × transverse diameter2 × AP 
diameter). Despite the inherent inaccuracies that arise from these 
geometric assumptions, all formulas reliably estimate gland volume and 
weight, with correlation coefficients greater than 0.90 with radical 
prostatectomy specimen weights, since 1 cm3 equals approximately 1 g of 
prostate tissue(9). The mature average prostate is between 20 and 25 g 
and remains relatively constant until about age 50, when the gland 
enlarges in many men (57). 
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PRESSURE FLOW STUDIES 
Pressure-flow studies consist of the simultaneous measurement of 
bladder pressure, abdominal pressure, and uroflow. The patient has a full 
bladder, and a free (uncatheterized) urine flow rate is obtained. 
A small (7–8 Fr) dual-lumen catheter is placed in each urethra; one 
lumen is used to measure bladder pressure and the other is used to infuse 
room temperature water or saline. A rectal catheter is placed to measure 
abdominal pressure. Detrusor pressure is obtained by subtracting the 
abdominal pressure from the total bladder pressure. 
Electromyography(EMG) of the external urethral sphincter is usually also 
recorded by means of patch or needle electrodes on the perineum. A high 
detrusor pressure–low flow pattern indicates bladder outlet obstruction, 
whereas a low pressure–low flow pattern indicates impaired detrusor 
contractility. The EMG recording indicates the degree of external 
sphincter activity and is most useful in identifying a lack of sphincter 
relaxation during voiding (dynamic obstruction).There are a variety of 
ways in which the results of pressure-flow studies may be interpreted. In 
general, a detrusor pressure of more than40 cm H2O with a uroflow less 
than 12 mL is considered obstructed; a detrusor pressure of less than 30 
cm H2O with a uroflow less than 12 mL indicates impaired detrusor 
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contractility; and detrusor pressures between30 and 40 cm H2O with a 
uroflow less than 12 mL is indeterminate (58).Another common way to 
analyze these studies is to plot the detrusor pressure at maximum flow vs 
the maximum flow rate. The Abrams-Griffiths nomogram is then used to 
divide results into obstructed, unobstructed and equivocal categories 
(figure). 
 
Pressure-flow studies are advantageous because they can be used to 
differentiate detrusor hypocontractility from bladder outlet obstruction. 
They are considered the gold standard for the diagnosis of bladder outlet 
obstruction and are widely used for both clinical and research purposes. 
However, they are invasive, time-consuming, labor-intensive, and 
proneto measurement error. Two or three consecutive studies must be 
performed because the results of a single test are highly variable(59). 
There tends to be a decrease in obstructive parameters with successive 
tests so that as many as 28% of patients will be redefined into a less 
obstructive Abrams-Griffiths category if the first study is compared with 
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subsequent studies(60). Furthermore, interpretation of the tests is not 
always straightforward, resulting in high intrainterpreter and inter inter 
preter variability (60). 
VIDEOURODYNAMICS 
Videourodynamic studies involve the measurement of urodynamic 
parameters along with the simultaneous fluoroscopic imaging of the 
bladder and urethra. For these studies, contrast material is infused in to 
the bladder instead of saline or water. In some instances, fluoroscopy is 
simply added to the pressure-flow study as described previously. In other 
cases, a triple-lumen bladder catheter is used, with the third, proximal 
lumen used to measure intraluminal urethral pressure. During filling, the 
proximal urethral pressure transducer (which is marked with a radiopaque 
marker) is positioned at the area of maximum resting urethral pressure 
(the external sphincter), and the distal transducer remains in the bladder 
to record intravesical pressure. This technique gives a more direct 
measurement of external sphincter activity than EMG electrodes. Some 
urodynamicists also omit the rectal catheter and simply measure total 
vesical pressure and urethral pressure. By adding fluoroscopic imaging to 
the measurements of pressures and flow rates, videourodynamic testing 
can be used to identify the location of bladder outlet obstruction (bladder 
neck, prostate, external urethral sphincter, bulbar urethra). Furthermore, 
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other abnormalities such as vesicoureteral reflux or urinary incontinence 
are easily demonstrated. The obstruction can be confirmed 
fluoroscopically by observing a narrowing of the urinary stream. This 
technique correlates well with results of pressure-flow studies and is less 
prone to technical difficulty(61).Despite the apparent advantages of 
videourodynamic studies, there has been no systematic evaluation of the 
utility of these studies in the evaluation of men with LUTS. 
CYSTOMETRY 
Cystometry is routinely performed as part of a pressure-flow or 
videourodynamics study. Pertinent abnormalities on cystometry include 
detrusor instability and diminished bladder compliance. Detrusor 
instability(DI) can be documented in approx 50% of men with LUTS 
and40% of men with documented obstruction(62). In patients who have 
DI before surgery, up to half may continue to have DI after 
prostatectomy, a suboptimal result(62). Unfortunately, there are currently 
no clinical or urodynamic criteria to determine which patients with 
bladder outlet obstruction and DI will do well after relief of the 
obstruction, and which patients will continue to have DI. Diminished 
bladder compliance has been demonstrated in 25–35%of men with 
bladder outlet obstruction(62). Older patients and those with severe 
obstruction demonstrate more significant compliance abnormalities than 
43 
patients who are younger and have less obstruction (62). This loss of 
compliance appears to be a generic response of the detrusor to obstruction 
(63). This finding is quite important because severe compliance 
abnormalities are clearly associated with the development of 
hydronephrosis and postrenal azotemia (63). Surgical intervention should 
be strongly considered for patients with significantly diminished 
compliance and bladder outlet obstruction. Such patients should have 
close urodynamic follow-up to assess for improvements in compliance 
following relief of the obstruction. 
SYMPTOMS AND URODYNAMIC FINDINGS 
Bladder outlet obstruction from BPH may result in medical 
conditions(urinary retention, renal insufficiency, bladder stones, recurrent 
urinary tract infections) that warrant surgical therapy. However, most 
men with prostatism do not have such conditions but instead have 
bothersome voiding symptoms. Numerous studies have failed to show 
any type of reproducible urodynamic finding that correlates with specific 
symptomatic complaints(64). Therefore, validated symptom scores for 
BPH are helpful to quantitate symptoms and assess response to therapy 
but cannot be used to diagnose bladder outlet obstruction. Urodynamic 
studies and symptom assessments appear to measure separate aspects of 
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lower urinary tract function that are probably related to some degree, but 
the nature of that relationship has not yet been defined. 
PREDICTIVE VALUE OF URODYNAMICS 
It is clear that 20–50% of men with LUTS do not have bladder 
outlet obstruction (62). Because the decision to perform surgery is often 
based on symptoms alone, one would expect that an equivalent 
proportion of patients undergoing surgery would also be unobstructed. If 
relief of obstruction equates with symptomatic success, one would expect 
limited symptomatic relief in those who are unobstructed preoperatively, 
but the literature on this point is inconclusive. A variety of studies have 
stratified symptomatic outcome based upon preoperative uroflowmetry 
results. Jensen and co-workers performed a prospective study of 139 men 
undergoing prostatectomy and found that those with a preoperative Qmax 
of greater than 15 mL/s had an increased likelihood of symptomatic 
treatment failure at 6 months (47). Pressure-flow studies have been 
extensively evaluated as potential predictors of treatment response 
following surgery (TURP or open prostatectomy).Some evidence exists 
that urodynamic data may yield relevant prognostic information. Abrams 
et al. reported a 72% success rate (symptomatic and flow rate 
improvement), which increased to 88% if pressure-flow criteria were 
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used to select patients for surgery (14).However, this study has been 
criticized for the unusually high failure rate (28%) in the initial group. 
Rollema et al. reported a better symptomatic outcome in 19 
preoperatively obstructed patients when compared with 10 unobstructed 
patients (65). Interestingly, 3 of the10 unobstructed patients reported 
significant postoperative improvement despite no demonstrable 
urodynamic changes. Data from these studies indicate that a policy of 
reserving surgical therapy for patients with demonstrated obstruction in 
preoperative pressure-flow studies may improve treatment outcomes, 
although most of these studies indicate a significant benefit to 
unobstructed patients as well. Kaplan et al. performed a retrospective 
review of 121 patients after TURP, with a mean follow-up of more than4 
years (62). There was no correlation with level of satisfaction with 
therapy and the presence or absence of bladder outlet obstruction on 
preoperative urodynamic tests (62). In another prospective study of 56 
patients, Roehrborn et al. reported no association between degree of 
preoperative obstruction and 6-month symptomatic response following 
TURP (66). 
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INDICATIONS FOR URODYNAMIC STUDIESIN MEN WITH 
LUTS 
To date, no urodynamic criteria have been found that predict 
treatment response to medical therapy for men with LUTS. The role of 
routine urodynamic testing before surgery is controversial. Urodynamic 
testing does appear to lower the surgical failure rate to some degree. 
Furthermore, although a significant number of unobstructed patients 
benefit from surgery, in such cases it is unclear what is being treated. 
Alternative therapies such as anticholinergic agents or biofeedback-
assisted pelvic floor muscle exercises may be equally beneficial and less 
morbid. However, the cost of performing routine urodynamic testing 
before surgery in all patients would be significant. The decision to obtain 
urodynamic studies must be individualized, but the eventual decision is 
largely based on the treatment philosophy of the physician. 
Men with persistent symptoms following surgical treatment to 
relieve bladder outlet obstruction should be studied. Such patients may 
have persistent obstruction, detrusor hypocontractility, detrusor 
instability, or diminished bladder compliance(67). Similarly, those with 
known or suspected neurologic disease may exhibit a wide range of 
urodynamic abnormalities. Proceeding with TURP or open prostatectomy 
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in these patients should be done only after other potential sources of 
voiding dysfunction have been identified and treated. Men with previous 
pelvic radiation or major pelvic surgery should also undergo urodynamic 
testing because these treatments may result in impaired bladder storage 
function, which could result in suboptimal results following surgery. In 
men with atypical clinical presentations (isolated symptoms of urgency 
and urge incontinence, severe symptoms and normal uroflow, young age), 
BPH-induced bladder outlet obstruction is less likely to be the cause of 
the symptoms, and it would therefore seem prudent to make the diagnosis 
clearly before proceeding with surgical therapy. 
Role of transition zone index in BPH 
The human prostate is composed of five histologically discernable 
zones. Hyperplasia of the transition zone compresses the central and 
peripheral zones into a structure termed the surgical capsule. In the adult 
human prostate the plane between the surgical capsule and transition zone 
is readily discernable on transrectal sonography or magnetic resonance 
imaging. The total prostate volume and transition zone index have been 
found to play an important role in BOO. Men with a total prostate volume 
>30ml have 3.5 times risk of having severe LUTS and 3-4 times the risk 
48 
of developing AUR. The value of volumetric measurements of the 
transition zone was recently reported in several studies.  
Tempany et al analysed the different zonal volumes and their 
changes after treatment with finasteride and concluded that the transition 
zone was more affected by medical treatment than was the peripheral 
zone(68). Tewari et al analyzed the differences in TZ and total volume 
reduction among patients whose peak urinary flow rate improved after 
finasteride therapy. They concluded that pre-treatment TZ index may help 
in predicting improvement in Q max after finasteride therapy. 
Furthermore it has been studied that the relation between the TZ and total 
gland volume was reported to correlate better than total volume alone 
with other clinical and urodynamic variables. In addition the TZ index 
correlation with the extent of BOO especially when the TZI >0.5 and it is 
also a predictor for acute urinary retention (69).Ohtani et al has shown 
that TZ volume and TZ index were useful parameters in preoperative 
decision making with regard to TURP (70). 
Need for new markers of Bladder Outlet Obstruction 
If we direct indications for treatment solely on symptoms and the 
subjective decline of quality of  life without assessing BOO, we will treat 
patients symptomatically (α-blockers) and after treatment failure 
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invasively (transurethral resection of the prostate). In that case, treatment 
of a symptomatic patient with BOO with a-blockers would make him 
asymptomatic but leave him obstructed with the consequence of ‘‘silent 
obstruction.’’ BOO, then, might lead to a damage of the lower and upper 
urinary tract. Patients with (unrecognised) BOO in the absence of LUTS 
should also get treatment because damage of the upper urinary tract is 
caused by BOO and not by LUTS which would be neglected. For these 
reasons, assessment of BOO and LUTS must be an essential part in the 
diagnosis of patients with BPH. Precise evaluation of BOO is only 
possible with pressure–flow studies; in the clinical routine, uroflowmetry, 
post void residual urine, and prostate volume are used to estimate BOO in 
men with BPH which have their own shortcomings. Thus there is a need 
for non invasive markers for BOO in men with BPH. 
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MATERIALS AND METHODS 
Study design 
Prospective cross-sectional diagnostic study 
Study centre 
The study was conducted at the Departments of Urology and 
Radiology, Madras Medical College and Rajiv Gandhi Government 
General hospital. 
Period of study 
The period of study was from August 2011 to February 2012. 
Study population 
A total of 50 patients were enrolled in the study. 
Inclusion criteria 
Men aged more than 50 years with lower urinary tract symptoms 
due to benign prostatic hyperplasia  
Exclusion criteria 
     Patients with any of the below mentioned characteristics were 
excluded from the study 
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1. Prostate cancer 
2.  Stricture urethra 
3.  Neurogenic bladder 
4.  Prostatitis/active urinary infection 
5.  Previous prostate surgery 
6.  Pelvic irradiation 
Methodology 
           50 patients were enrolled for the study. Informed consent was 
obtained after explaining the need for the procedure and possible 
complications. Approval by the Ethical committee of the institute where 
the study was undertaken was obtained prior to conduct of the study. At 
initial presentation, a thorough history was obtained and physical 
examination done.  
          The grading of prostatic size on rectal examination was done as 
follows: 
Normal: encroaches 0-1cm into the rectal lumen 
Gr 1: encroaches 1-2cm into the rectal lumen 
Gr 2: encroaches 2-3cm into the rectal lumen 
Gr 3: encroaches 3-4cm into the rectal lumen 
Gr 4: encroaches more than 4cm into the rectal lumen 
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International prostate symptom score(IPSS) was completed and a 
blood sample for measuring the patient’s serum PSA was taken. Patients 
underwent uroflowmetry using Status Meditech flow meter. Post void 
residual urine estimation was done at the end of uroflow using 3.5 mHz 
ultrasound array. Transabdominal sonography of the kidneys, bladder and 
prostate was performed using 3.5 – 5 mHz array. The bladder wall 
thickness (DWT) was measured between the two hyperechoic lines which 
represent the mucosa and the adventitia.  Two different points were 
measured at a bladder capacity of 200-250ml and the mean of both 
obtained. Median lobe projection of the prostate into the bladder was 
measured in a sagittal scan at the same time. 
       TRUS was performed by the radiologist unaware about the 
findings of uroflowmetry and pressure flow studies. The prostate 
dimensions were determined using a 7.5mHztransrectal probe. The 
prostate was imaged from base to apex in two views – sagittal/ transverse, 
documenting the presence of prostatic abnormality and measuring the 
volume using the ellipsoid formula,i.e., 
Volume=      Π/6 x (height x width x length)in ml 
    Calculating the volumes requires the assumption that both prostate 
and transition zones are ellipsoidal. 
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  The transition zone(TZ) is identified as an area of heterogenous 
echogenicity compared to the hypoechoic peripheral zone (PZ).The TZ 
volume was calculated using the same formula and maximum diameters 
were used for each measurement. Transition zone index was defined as 
the ration between TZ volume and total gland volume (TZI= TZV/ PV). 
Urine culture and sensitivity were done and confirmed to be sterile prior 
to performing urodynamic studies. 
 
    Urodynamic examination was done 1to 3weeks after the 1st visit. 
Urodynamic investigations were performed on a Laborie medical 
technology machine. Intravesical pressure was recorded by means of 5Fr 
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double lumen urethral catheter. Intraabdominal pressure was measured 
using 5Fr balloon catheter in the rectum. The pressure sensors were 
zeroed to atmospheric pressure before introducing them into the patient. 
The bladder was filled with saline at room temperature at the rate of 20-
50ml/min. All studies were done with patients in sitting posture. Filling 
of the bladder was stopped when patient expressed a strong desire to void 
and filling catheter was removed. Patient was allowed to void in privacy 
in sitting posture. Voided volume and detrusor pressure at maximal flow 
rate were noted. The AG number was then calculated as, AG 
number=Pdet.Qmax – 2Qmax. Based on the AG number, patients were 
considered obstructed (AG>40) or non obstructed (AG<40). 
STATISTICAL ANALYSIS 
Descriptive statistics were used to illustrate the study population. 
All parameters were continuous variables and Pearson’s coefficient of 
correlation was used for analysis. The statistical significance of these 
correlations was assessed using a two sided p-value. A p-value of <0.05 
was considered statistically significant. The Chi Square test was used to 
assess the statistical significance of TZ index cut off value in predicting 
bladder outlet obstruction. A commercially available computer software 
package (SPSS version 10) was used for statistical analysis. 
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RESULTS 
The duration of study was from August 2011 to February 2012.A 
total of 50 patients were included in the study. 
AGE 
 The age wise patient distribution is shown in Table-1.most of the 
patients (48%) belonged to the age group of 61-65 years. The mean age 
of patients was 63.78 years and ranged between 52-78 years. 
Table-1 
Age group(yr) Total 
51-55 4 
55-60 8 
56-60 1 
61-65 24 
66-70 8 
70-75 2 
76-80 3 
 
Duration of symptoms 
 All patients had symptoms of LUTS for a period ranging between 
1-24 months, with a mean of 5.4 months. Table -2 shows distribution of 
duration of LUTS among patients. 
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Table-2 
Duration of symptoms Number of pts 
<=3 months 20 
>12 months 1 
3-6months 19 
6-9 months 3 
9-12 months 7 
 
NATURE OF SYMPTOMS 
 Among the 50 patients, obstructive LUTS was noted in 42and 
irritative LUTS in 40. 64% had both obstructive and irritative symptoms. 
(Table-3)   
Table-3 
Irritative LUTS 
No Yes Total 
Obstructive LUTS 
No 0 8 8 
Yes 10 32 42 
Total 10 40 50 
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IPSS 
 According to the IPSS scoring system,64% patients had moderate 
symptoms(score8-19) and 24% had severe symptom score(20-35). 
(Table-4) 
 On combining the patient symptoms with IPSS grades; patients in 
the mild grade had predominantly irritative symptoms. (Table-5) Ten 
patients in the severe IPSS grade had both obstructive and irritative 
LUTS. 
Table-4 
IPSS Grade Total 
Mild 6 
Moderate 32 
Severe 12 
Grand Total 50 
Table-5 
IPSS 
grade 
obstructive 
LUTS irritative LUTS 
Both irritative and 
obstructive LUTS 
Mild 0 3 3 
Moderate 9 4 19 
Severe 1 1 10 
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RECTAL EXAMINATION OF THE PROSTATE 
 On examination 36 out of 50patients had only grade 1 prostatic 
enlargement.  
Table-6 
DRE PROSTATE TOTAL 
Grade 1 36 
Grade 2 14 
Grand Total 50 
 
SERUM CREATININE 
When patients symptoms were analysed according to their serum 
creatinine18% of patients with moderate symptoms and just 9% of 
patients with severe symptoms had azotemia. This shows that the severity 
of symptoms may not be indicative of the degree of compromise in renal 
function due to BPH (Table-7). 
Table-7 
S.Creatinine IPSS mild Moderate Severe 
<=1.6mg% 6 26 11 
>1.6mg% 0 6 1 
Total 6 32 12 
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PROSTATE SPECIFIC ANTIGEN 
 34% of patients with PSA > 1.5 ng/ml had severe symptoms, 
whereas, only 10% of patients with PSA <1.5ng/ml had severe 
symptoms(Table-8). 
Table-8 
PSA ng/ml 
IPSS Grade 
 
Grand Total 
        Mild Moderate severe 
<1.5 4 15 2 21 
1.5-4 2 17 10 29 
Grand Total 6 32 12 50 
 
POST VOID RESIDUAL URINE (PVR) 
 The PVR of patients studied ranged from 5 ml to150 ml (mean -46.2 
ml).40% of patients had a PVR of > 50 ml. (figure-1) 
Figure-1 
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Table -9 shows the relationship of PVR to IPSS scores. None of the 
patients with mild symptoms had large PVR(>50 ml)whereas 50% of 
patients with large PVR had severe symptoms. 
Table-9 
PVR IPSS mild Moderate Severe 
<50ml 6 22 2 
>50ml 0 10 10 
Total 6 32 12 
 
PROSTATE VOLUME ON TRUS 
Only one patient with mild symptoms had a prostate volume > 
30ml, while 84% of patients with severe symptoms had a prostate volume 
> 30ml. (Table-10) 
Table-10 
Prostate 
size IPSS mild Moderate Severe Total 
<30ml 5 14 2 21 
>30ml 1 18 10 29 
Total 6 32 12 50 
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Table -11 compares the prostate volume on TRUS with grade on 
rectal examination. Only 48% of prostates that were grade 2 on rectal 
examination had a volume > 30ml. 
Table-11 
Prostate size DRE Grade 1 DRE Grade 2 Total 
<30ml 17 4 21 
>30ml 19 10 29 
Total 36 14 50 
 
DETRUSOR WALL THICKNESS(DWT) 
35 Out of 50 patients had a DWT < =5mm (figure-2). None of the 
patients with DWT > 5mmhad mild range IPSS scores, while only 26% 
of patients who were severely symptomatic had a DWT> 5mm. 
Figure-2 
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Table 12 shows relationship between DWT and PVR.73% of 
patients with a DWT> 5mm had a PVR> 50 ml. 
Table -12 
DWT PVR <50ml PVR > 50ml 
<=5mm 26 9 
>5mm  04 11 
Total 30 20 
 
UROFLOWMETRY 
54% of patients had a peak flow rate < 10 ml/sec. There were nine 
patients who had a Qmax> 15 ml/sec.(figure-3)  
93% patients with detrusor thickness> 5mm had a Qmax< 10ml 
(Table-13), while 48% of patients with Q max < 10 ml had a DWT<= 
5mm.  
Figure -3 
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Table-13 
DWT / Q max <10 10-15 >15 
<=5mm 13 13 9 
>5mm 14 1 0 
Total 27 14 9 
 
Two thirds of patients with poor flow rates (<10ml) had a PVR > 50 ml, 
(Table -14); while all patients with Q max >15ml/sec had a PVR < 50 ml. 
Table-14 
Q max Group 
PVR group 
Grand Total 
<50ml >50ml 
<10ml/sec 9 18 27 
>15ml/sec 9 0 9 
10-15ml/sec 12 2 14 
 
ABRAMS GRIFFITH NUMBER (AG number) 
There were 22 patients in the obstructed group (AG> 40) and 28 
patients had an AG number <= 40 (figure-4). 
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Figure-4 
 
Table -15 shows that 21 out of 22 patients with bladder outlet 
obstruction had a Qmax< 10ml/sec. Only 6 patients out of 27(22%) had a 
Qmax< 10 ml/sec but were not obstructed on pressure flow studies (AG  
number < 40). 
Table-15 
Count of AG  
number group 
AG number 
Non obstructed 
Obstructed Equivocal Grand  
Total 
Q max Group <20 >40 21-40 
<10ml/sec 2 21 4 27 
>15ml/sec 6 0 3 9 
10-15ml/sec 11 1 2 14 
Grand Total 19 22 9 50 
None of the patients with DWT more 5mm had an AG number of 
less than 20, while 14out 15 patients with DWT > 5mm had BOO 
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according to AG number signifying that DWT is a very good predictor of 
bladder outlet obstruction  (Table-16). 
Table-16 
DWT / AG no. <20 20-40 >40 
<=5mm 19 8 8 
>5mm 0 1 14 
Total 19 9 22 
 
Only one patient with AG number less than 20 had PVR more than 
50 ml. 80% of patients with PVR more than 50 ml had AG number of 
more than 40.(Table-17) When correlating the IPSS grade to AG number 
83% of those with severe symptoms were obstructed. However among 
those obstructed on pressure flow studies only 45% had severe range 
IPSS symptoms(Table 18). 
Table-17 
Count of PVR AG number 
Grand Total 
PVR group <20 >40 21-40 
<50ml 18 6 6 30 
>50ml 1 16 3 20 
Grand Total 19 22 9 50 
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Table -18 
IPSS Grade/ 
AG no. <20 >40 21-40 Grand Total 
Mild 6 0 0 6 
Moderate 12 12 8 32 
Severe 1 10 1 12 
Grand Total 19 22 9 50 
 
TRANSITION ZONE INDEX (TZI) 
Figure-5shows the scatter diagram of TZ index in the study 
patients. Mean TZ index was 0.44. Transitional zone index if prostate 
volume < 30ml, was 0.3-0.63(mean-0.44) and if > 30ml it was 0.27-
0.8(mean-0.53).  
Figure-5 
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As shown in Table -19, the transition zone index value was 
statistically significant in differentiating obstructed from non obstructed 
patients. (p<0.001) 
Table -19 
Parameter AG <=40 AG>40 p-value 
Prostate volume, ml 28.35 45.46 <0.0005 
Transition zone vol.,ml 11.7 26.4 <0.0001 
TZ index 0.41 0.58 <0.0001 
 
TZ Index cut off value for outlet obstruction 
A TZ index value of greater than 0.45 had 100% sensitivity, 
75%specificity,76%positive predictive value for diagnosing obstruction. 
Table-20 shows the statistical correlation of transition zone index value of 
0.45 with the Abrams Griffith number. The p-value was highly significant 
(<0.001). 
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Table-20 
TZI 
AG number Group 
  
Grand Total <20 >40 21-40 
<=0.45 16  5 21 
>0.45  4 22 3 29 
Grand Total 20 22 8 50 
P<0.001 in chi square test 
CORRELATION STATISTICS ON REGRESSION ANALYSIS 
Table-21 
r 
value/ 
p value 
IPSS PVR Q max PV TZ vol AG No. PSA 
T Z 
index 
0.732/ 
<0.0000
1 
0.51/ 
0.0001 
0.64/ 
0.000001 
0.09/ 
0.03 
0.58/ 
0.0007 
0.7/ 
0.000001 
0.39/ 
0.005 
PSA 0.44   0.54/ 
0.0005 
0.57/ 
0.00001 
0.64/ 
0.000003 
1 
IPSS 1 0.65      
AG 
No. 
   0.45/ 
0.001 
0.61/ 
0.00002 
1 0.64/ 
0.00003 
 
IPSS, PVR, Peak flow rates, transition zone volume, AG number, 
serum PSA had strong correlations with the Transition zone index  
(table-21). The strongest correlation was with the IPSS score and Abram-
Griffiths number (r=0.7) indicating good predictability for transition zone 
index in diagnosing bladder outlet obstruction. 
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DISCUSSION 
The correlation between various BPH parameters and prostate size 
has been debated in the literature. The use of different symptom scores 
and various urodynamic parameters, including peak flow rate and post 
void residual urine (PVR) have contributed to a lack of consensus. 
In our study, majority of patients had IPSS scores in the moderate 
range- mean score was 14.98 which are typical of men who visit our 
clinics. The mean age of patients was 63.7years, comparable to other 
studies, evaluating the role of transition zone (TZ)index; as both total 
prostate volume and transition zone volume increase with increasing age. 
In the present study, serum PSA showed positive correlation with 
the IPSS scores(r=0.44). Serum PSA reflects the total gland volume more 
so for the TZ volume as it is produced by the TZ epithelial cells. Men 
with LUTS and higher PSA are therefore likely to have larger TZ 
volumes and hence more symptoms. The relationship between symptoms 
and total prostate volume (PV) in 803 patients have been described with 
no correlation detected (71). However in the present study, IPSS is 
strongly correlated with TZ volume, PV and TZ index. 
Comparing the prostate grade on rectal examination with TRUS 
estimation of prostate volume, our study showed that they were poorly 
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correlated. BPH occurs in the TZ and rectal examination cannot assess 
the TZ. To avoid any evaluation bias, we measured the total PV/TZ 
volume using TRUS before performing pressure flow studies- the 
reference standard test. 
Oelke et al studied 168 men with LUTS and concluded that 
Detrusor Wall Thickness (DWT) was the most accurate test to determine 
BOO, with a specificity of 95% and positive predictive value of 94% 
(72). However in the present study, detrusor wall thickness did not 
correlate with the severity of IPSS scores. DWT is also influenced by 
detrusor overactivity, incontinence, low compliance, dysfunctional 
voiding or detrusor hypocontractility. We had 30% of patients with DWT 
< 5mm with poor flow rates, indicating possible myogenic failure. 
Uroflow and PVR 
22 percent of patients with low flow rates were not obstructed on 
pressure flow studies; so uroflow is not specific for BOO. Likewise 20% 
of patients with PVR > 50 ml were not obstructed urodynamically. 
Residual urine or low Q max can be caused by BOO, detrusor 
underactivity or both indicating that these tests are poor predictors of 
obstruction. 
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While correlating IPSS grade to the AG number, we found that 
among those with BOO, only 45% patients had symptoms in the severe 
range; thereby indicating their unreliability in predicting BOO. 
Transition zone index(TZI) 
Greene et al noted that patients with clinical BPH had a TZ volume 
of 24.81+14.4 ml, in contrast to a volume of 6.14+3.2 ml in those without 
clinical BPH (73).Kaplan et al was the first to report TZ index as a more 
sensitive marker of BPH and showed TZI>0.5 to be an indicator of 
significant BOO (15). Kurita et al reported that men with a TZI >0.65had 
higher risk of developing acute urinary retention (74). Milonas et al 
reported that the highest risk of developing AUR was in patients with a 
TZI> 0.6 (75).The possible reasons for higher cut off of TZ Index in these 
series could be selection of men with AUR. Lepor et al reported that the 
total prostate volume, TZ volume and TZ index were not directly related 
to the symptom score and only weakly related to the flow rate (76). 
Discrepancy between the two reports was due to different inclusion 
criteria. The present study included men with BPH and LUTS like that of 
Kaplan et al and unlike that of Lepor et al (15,76). 
 Witjes et al in a prospective study on 150 patients found that TPV, 
TZV and TZI correlated equally well with age but weakly with pressure 
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flow studies (77). The problem with this study is that it consisted of men 
with a wide age range(30-85 years);prostate volume and symptom scores 
which could have resulted in the measured discrepancy. 
Our results demonstrate a significant strong correlation between TZ 
index and IPSS score, uroflow, PVR, Serum PSA and AG number in men 
with LUTS due to BPH. Similar results were obtained in a study by Chen 
et al. They found that in elderly Asian men with BPH/LUTS, degree of 
BOO was significantly correlated with Total prostate volume and 
transition zone index, mean value being 0.46 in those with BOO (78). 
Intuitively these results are consistent with the hypothesis that the 
symptoms and urodynamic abnormalities associated with BPH are caused 
by mechanical or static compression by the prostate. Small prostates with 
smaller TZ volume may also result in severely symptomatic patients with 
markedly impaired flow rates and high voiding pressures. 
It is conceivable that each patient may have a critical volume of TZ 
relative to the prostate; which results in bladder outlet obstruction. The 
strongest correlation of TZ index was with IPSS score(r=0.732) and AG 
number (r=0.7). Population and autopsy studies suggest a racial variance 
in prostate volume. In a study by Choi et al, they found that mean TZ 
index was significantly higher in Korean and Afro-American men 
(TZI=0.45) versus Caucasian and Hispanic men(TZI=0.39) (79). 
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 We therefore decided to develop a cut off point for the TZ index 
which combines the greatest sensitivity with maximum specificity, i.e 
efficiency of a test. At a TZ index cut –off of >0.45, all patients with 
outlet obstruction were detected while the specificity remained high at 
75%.(Table-22)The implication of the finding suggests that men with 
LUTS and high transition zone index would respond better to therapies 
designed to reduce TZ volume medically or surgically. 
Table-22 
TZ 
index 
No. of 
pt 
With 
BOO 
No 
BOO 
Sensitivit
y 
Specificit
y 
PP
V 
>0.3 48 22 26 100% 
7% 45
% 
>0.4 35 22 13 100% 
50% 60
% 
>0.45 29 22 7 100% 
75% 76
% 
>0.5 24 19 5 83% 
84% 80
% 
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CONCLUSION 
 This study demonstrates that transition zone index is 
significantly correlated with symptom scores, PVR, 
uroflowmetry, pressure flow studies. 
 Therefore transition zone index is a good non invasive tool 
to assess bladder outlet obstruction in men with BPH. 
 Using a Transition Zone index cut off of > 0.45, can identify 
obstruction with 100% sensitivity, 75% specificity and 76% 
positive predictive value. 
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APPENDIX-1 INFORMED CONSENT FORM 
Title of the study:ROLE OF TRANSITION ZONE INDEX IN ASSESSING 
BLADDER OUTFLOW OBSTRUCTION DUE BENIGN PROSTATIC 
HYPERPLASIA 
Name of the Participant:  
Name of the Principal Investigator: Dr.ARUN KUMAR. K 
Name of the Institution:  
Madras Medical College and Rajiv Gandhi Government Hospital, Chennai- 3 
Name and address of the sponsor / agency: Nil 
Documentation of the informed consent 
I have read the information in this form (or it has been read to me). I was free to ask 
any questions and they have been answered. I am over 18 years of age and, 
exercising my free power of choice, hereby give my consent to be included as a 
participant in “ROLE OF TRANSITION ZONE INDEX IN ASSESSING 
BLADDER OUTFLOW OBSTRUCTION DUE TO BENIGN PROSTATIC 
HYPERPLASIA”  
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
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5. I have been informed the investigator of all the treatments I am taking or have 
taken in the past ____ months including any native (alternative) treatment. 
6. I have been advised about the risks associated with my participation in this study. 
7. I agree to cooperate with the investigator and I will inform him/her immediately if I 
suffer unusual symptoms.  
8. I have not participated in any research study within the past _________month(s).  
9. I am aware of the fact that I can opt out of the study at any time without having to 
give any reason and this will not affect my future treatment in this hospital.  
10. I am also aware that the investigator may terminate my participation in the study 
at any time, for any reason, without my consent.  
11. I hereby give permission to the investigators to release the information obtained 
from me as result of participation in this study to the sponsors, regulatory authorities, 
Govt. agencies, and IEC. I understand that they are publicly presented. 
12. I have understood that my identity will be kept confidential if my data are publicly 
presented 
13. I have had my questions answered to my satisfaction. 
14. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact the 
investigator. By signing this consent form I attest that the information given in this 
document has been clearly explained to me and understood by me, I will be given a 
copy of this consent document. 
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For adult participants: 
Name and signature / thumb impression of the participant (or legal representative if 
participant incompetent) 
Name _________________________ Signature_________________ 
Date________________ 
Name and Signature of impartial witness (required for illiterate patients): 
Name _________________________ Signature_________________ 
Date________________ 
Address and contact number of the impartial witness: 
Name and Signature of the investigator or his representative obtaining consent: 
Name _________________________ Signature_________________ 
Date________________ 
For Children being enrolled in research: 
Whether child’s assent was asked: Yes / No (Tick one) 
[If the answer to be above question is yes, write the following phrase: 
You agree with the manner in which assent was asked for from your child and given 
by your child. You agree to have your child take part in this study]. 
[If answer to be above question No, give reason (s) 
:___________________________________. 
Although your child did not or could not give his or her assent, you agree to your 
child’s participation in this study. 
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Name and Signature of / thumb impression of the participant’s parent(s) (or legal 
representative) 
Name _________________________ Signature_________________ 
Date________________ 
Name _________________________ Signature_________________ 
Date________________ 
Name and Signature of impartial witness (required for parents of participant child 
illiterate): 
Name _________________________ Signature_________________ 
Date________________ 
Address and contact number of the impartial witness: 
__________________________________ 
Name and Signature of the investigator or his representative obtaining consent : 
Name _________________________ Signature_________________ 
Date________________ 
NOTE 
For observational studied in nature or those in which only patient’s tissue, body fluids 
are collected for any kind of analysis, the following elements in the patient 
information leaflet will need be included – background of the study: the purpose for 
which the sample will be used: confidentially of data are right to refuse to give 
specimens should be included. 
Points 6, 7,8,9,10,11 of consent document may be excluded in such cases. 
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Appendix -1-informed consent form 
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Appendix-2  Patient Information sheet 
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APPENDIX -3 Patient Proforma 
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APPENDIX 3-IPSS SCORECARD 
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APPENDIX-3  IPSS  SCORE- TAMIL 
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Appendix -4  MASTER CHART 
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APPENDIX-4 MASTER CHART 
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APPENDIX-5       ETHICAL COMMITTEE APPROVAL 
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APPENDIX-6 LIST OF ABBRIEVIATIONS 
BPH  -  Benign prostatic hyperplasia 
BOO  -  Bladder outflow obstruction 
PV  -  prostate volume 
TZV  -  Transition zone volume 
TZI  -  Transition zone index 
TRUS -  Transrectalultrasonogram 
PVR  -  Post void residual urine 
LUTS -  lower urinary tract symptoms 
AG number -  Abrams-Griffith number 
PSA  -  Prostate Specific antigen 
Q max -  Peak flow rate 
DWT  -  Detrusor wall thickness 
IPP  -  IntravesicalProtrusion of prostate 
IPSS  -  International Prostate symptom score 
DRE  -  Digital Rectal Examination 
